<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117836">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02132169</url>
  </required_header>
  <id_info>
    <org_study_id>14-100-0006</org_study_id>
    <nct_id>NCT02132169</nct_id>
  </id_info>
  <brief_title>A Multi-Center Study Evaluating the Safety of AC-170 0.24%</brief_title>
  <official_title>A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aciex Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aciex Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in
      Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic
      disease (including allergic conjunctivitis).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Tolerability of AC 170 0.24% compared to its vehicle</measure>
    <time_frame>up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tolerability of AC 170 0.024% compared to its vehicle will  be measured at Visit 1-3. Subjects will assess their comfort based on an approved scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of AC 170 0.024% compared to its vehicle</measure>
    <time_frame>Up to 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety measures (adverse events, etc.) of AC 170 0.024% compared to its vehicle will be measured at Visit 1-4 and 5 (for subset of patients).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">501</enrollment>
  <condition>Atopc Disease (Including Allergic Conjunctivitis)</condition>
  <arm_group>
    <arm_group_label>AC-170 0.24%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-170 0%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: AC-170 0.24%</intervention_name>
    <arm_group_label>AC-170 0.24%</arm_group_label>
    <other_name>1 drop in each eye 2 times daily for up to 6 weeks</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-170 0%</intervention_name>
    <arm_group_label>AC-170 0%</arm_group_label>
    <other_name>1 drop in each eye 2 times daily for up to 6 weeks</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 2 years of age

          -  be able to self-administer eye drops or have a parent/legal guardian available for
             this purpose

          -  if less than 18 years old have a history or family history of atopic disease
             (including allergic conjunctivitis)

          -  have ocular health within normal limits

        Exclusion Criteria:

          -  known contraindications or sensitivities to the study medication or its components

          -  any ocular condition that, in the opinion of the investigator, could affect the
             subjects safety trial parameters

          -  use of disallowed medication during the period indicated prior to the enrollment or
             during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tom Cavanagh</last_name>
    <phone>917-969-9339</phone>
    <email>tcavanagh@aciexrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allie Griffin</last_name>
      <phone>978-685-8900</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>April 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
